November 23rd 2024
FDA's approval will allow Kedrion to manufacture Ryplazim (plasminogen, human-tvmh), the only FDA-approved therapy for treating PLGD-1, at facility in Bolognana, Italy.
November 19th 2024
It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.
Implications and Opportunities of Applying QbD Principles to Analytical Measurement
The authors present two concepts to improve robustness and facilitate continuous improvement in analytical methods.
WHO Denies Improper Pharmaceutical-Industry Influence on Pandemic Response
January 28th 2010Keiji Fukuda, special adviser on pandemic influenza to the World Health Organization's (WHO) director-general, told a hearing at the Council of Europe that WHO's response to the influenza (H1N1) pandemic was not improperly influenced by the pharmaceutical industry.
FDA's Justina A. Molzon on ICH and Harmonization
December 3rd 2009Pharmaceutical Technology talks to FDA's Justina A. Molzon about current discussions with international regulators, and how, after 20 years of harmonization activities and the common technical document, ICH has benefited regulatory authorities.